TUBA4A
ENSG00000127824
Target class
Structural protein
Chromosome
2
Approved drugs
19
Clinical candidates (approved and in development)
83
- Approved drugs
- 19
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 83
- Chemical probe available
- No
- Target name
- TUBA4A
- Gene name
- Tubulin alpha 4a
- Gene symbol
- TUBA4A
- Previous gene symbols
- TUBA1
- Protein name
- Tubulin alpha-4A chain (EC 3.6.5.-) (Alpha-tubulin 1) (Testis-specific alpha-tubulin) (Tubulin H2-alpha) (Tubulin alpha-1 chain)
- FLJ30169
- H2-ALPHA
- Gene biotype
- Protein coding
- Gene family
- Tubulin alpha family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 239.9
- Tissue specificity (Gini)
- 0.46
- Tissue specificity (tau)
- 0.762
- KEGG gene identifiers
- hsa:7277
- Protein interaction confidence
- 0.836143
- Protein interaction partners
- 42
- R-HSA-114608
- R-HSA-1445148
- R-HSA-190840
- R-HSA-190861
- R-HSA-2132295
- R-HSA-2467813
- R-HSA-2500257
- R-HSA-2565942
- R-HSA-3371497
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-389957
- R-HSA-389960
- R-HSA-389977
- R-HSA-437239
- R-HSA-5610787
- R-HSA-5620912
- R-HSA-5620920
- R-HSA-5620924
- R-HSA-5626467
- R-HSA-5663220
- R-HSA-6807878
- R-HSA-6811434
And 13 more, listed on the interactive page.
- End position
- 219277902
- Start position
- 219249710
- Chromosome
- 2
- Strand
- Reverse
- Cytoplasm, cytoskeleton.
- Microtubules
- Primary cilium
- Tissue specificity (tau)
- 0.762498
- Expression inequality (Gini)
- 0.45971
Expression in transcripts per million
- Whole Blood
- 239.9
- Muscle - Skeletal
- 203.54
- Skin - Sun Exposed (Lower leg)
- 202.82
- Skin - Not Sun Exposed (Suprapubic)
- 197.32
- Brain - Frontal Cortex (BA9)
- 175.87
Expression in transcripts per million
- Whole Blood239.9
- Muscle - Skeletal203.54
- Skin - Sun Exposed (Lower leg)202.82
- Skin - Not Sun Exposed (Suprapubic)197.32
- Brain - Frontal Cortex (BA9)175.87
- Cells - EBV-transformed lymphocytes164.78
- Brain - Cortex132.11
- Brain - Cerebellar Hemisphere132.02
- Brain - Cerebellum118.92
- Esophagus - Mucosa108.41
- Brain - Anterior cingulate cortex (BA24)83.79
- Spleen82.96
- Testis77.86
- Vagina73.46
- Artery - Aorta69.32
- Brain - Hypothalamus67.04
- Esophagus - Muscularis46.39
- Small Intestine - Terminal Ileum46.14
- Artery - Tibial45.79
- Esophagus - Gastroesophageal Junction45.52
- Minor Salivary Gland45.51
- Brain - Nucleus accumbens (basal ganglia)44.85
- Brain - Amygdala44.48
- Colon - Sigmoid41.94
- Heart - Left Ventricle41.91
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005829
- GO:0005856
- GO:0005874
- GO:0005929
- GO:0015630
- GO:0070062
- GO:0005515
- GO:0019901
Related records
Trials (9,112)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (88)
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor
- Davunetide Tubulin stabiliser